Gout and risk of chronic kidney disease and nephrolithiasis: Meta-analysis of observational studies

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Roughley, Matthew J ^a   Belcher, John ^a   Mallen, Christian D ^a   Roddy, Edward ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DATA BASE; DISEASE ASSOCIATION; GOUT; HUMAN; META ANALYSIS; NEPHROLITHIASIS; OBSERVATIONAL STUDY; PREVALENCE; PRIMARY MEDICAL CARE; RISK FACTOR; SELF REPORT; SYSTEMATIC REVIEW; ADULT; COMORBIDITY; FEMALE; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

ADULT; CASE-CONTROL STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; GOUT; HUMANS; MALE; MIDDLE AGED; NEPHROLITHIASIS; OBSERVATIONAL STUDIES AS TOPIC; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

EID: 84928015204     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0610-9     Document Type: Article

References (64)

1. Kuo C, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014;0:1-7.
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12:223.
3. Berger L, Yü TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605-13.
4. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74-82.
5. Yü TF, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967;67:1133-48.
6. Yü TF, Berger L. Impaired renal function gout: its association with hypertensive vascular disease and intrinsic renal disease. Am J Med. 1982;72:95-100.
7. Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72:92-9.
8. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-81.
9. Bello AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl. 2005;68:s11-7.
10. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165:742-8.
11. Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;13:R39.
12. El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? Cleve Clin J Med. 2010;77:919-28.
13. Scales C, Smith A, Hanley J, Saigal C. Prevalence of kidney stones in the United States. Eur Urol. 2012;62:160-5.
14. Parmar MS. Kidney stones. BMJ. 2004;328:1420-4.
15. Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Curr Rheumatol Rep. 2007;9:251-7.
16. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68:1230-5.
17. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293:455-62.
18. Cappuccio FP, Siani A, Barba G, Mellone MC, Russo L, Farinaro E, et al. A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens. 1999;17:1017-22.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:s1-266.
20. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2 Dec 2011.
21. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
22. Chen N, Wang W, Huang Y, Shen P, Pei D, Yu H, et al. Community-based study on CKD subjects and the associated risk factors. Nephrol Dial Transplant. 2009;24:2117-23.
23. Hsu C, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease - 25-year follow-up. Arch Intern Med. 2009;169:342-50.
24. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49:141-6.
25. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;12:36.
26. Johnson ES, Smith DH, Thorp ML, Yang X, Juhaeri J. Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study. BMC Nephrol. 2011;12:17.
27. Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63.
28. Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14:R83.
29. Liote F, Lancrenon S, Lanz S, Guggenbuhl P, Lambert C, Saraux A, et al. GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n=1003). Joint Bone Spine. 2012;79:464-70.
30. Lin MY, Chiu YW, Lee CH, Yu HY, Chen HC, Wu MT, et al. Factors associated with CKD in the elderly and nonelderly population. Clin J Am Soc Nephrol. 2013;8:33-40.
31. Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52:111-7.
32. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012;7:e50046.
33. Kok VC, Horng JT, Lin HL, Chen YC, Chen YJ, Cheng KF. Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. BMC Cardiovasc Disord. 2012;12:108.
34. O'Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1972;31:166-9.
35. Schaffalitzky De Muckadell OB, Gyntelberg F. Occurrence of gout in Copenhagen males aged 40-59. Int J Epidemiol. 1976;5:153-8.
36. Currie WJ. The gout patient in general practice. Rheumatol Rehabil. 1978;17:205-17.
37. Currie WJ, Turmer P. The frequency of renal stones within Great Britain in a gouty and non-gouty population. Br J Urol. 1979;51:337-41.
38. Kramer HM, Curhan G. The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42.
39. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003;64:1022-6.
40. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher Jr. HR, Saag KG. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis. 2005;64:267-72.
41. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65:1368-72.
42. Padang C, Muirden KD, Schumacher HR, Darmawan J, Nasution AR. Characteristics of chronic gout in Northern Sulawesi, Indonesia. J Rheumatol. 2006;33:1813-7.
43. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher H, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925-34.
44. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609-13.
45. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11.
46. Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72:694-700.
47. Ando R, Nagaya T, Suzuki S, Takahashi H, Kawai M, Okada A, et al. Kidney stone formation is positively associated with conventional risk factors for coronary heart disease in Japanese men. J Urol. 2013;189:1340-6.
48. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125:679-687.e1.
49. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66:1311-5.
50. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900.
51. Kellgren JH, Jeffrey MR, Ball J. The epidemiology of chronic rheumatism. Oxford: Blackwell; 1963.
52. Bennett PH, Wood PHN. Population studies of the rheumatic diseases. Amsterdam: Excerpta Medica Foundation; 1968.
53. Glynn LG, Anderson J, Reddan D, Murphy AW. Chronic kidney disease in general practice: prevalence, diagnosis, and standards of care. Ir Med J. 2009;102:285-8.
54. de Lusignan S, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22:234-41.
55. Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci. 2012;17:656-69.
56. Rosenfeld JB. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. Adv Exp Med Biol. 1974;41:581-96.
57. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406-13.
58. Roddy E, Menon A, Hall A, Datta P, Packham J. Polyarticular sonographic assessment of gout: a hospital-based cross-sectional study. Joint Bone Spine. 2013;80:295-300.
59. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991;34:141-5.
60. Soltész P, Kerekes G, Dér H, Szücs G, Szántó S, Kiss E, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev. 2011;10:416-25.
61. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431-46.
62. National Institute for Health and Care Excellence. CG182 chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. London: National Institute for Health and Care Excellence; 2014.
63. Türk C, Knoll T, Petrik A, Sarica K, Skolarikos A, Straub M, et al. Guidelines on Urolithiasis. 2014. http://uroweb.org/guideline/urolithiasis/. Accessed 16 Mar 2015.
64. Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010;49:105-11.